GeneQuantum Healthcare

Fineline Info & Tech (Flcube.com) provides you with comprehensive information about
GeneQuantum Healthcare, including details on the company, its pharmaceuticals, policies, deals, healthcare enterprises, research and development, hospitals, legal patents, and internet healthcare. More information about GeneQuantum Healthcare please access Flcube.com

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has released the "Implementation Rules for the Exit Mechanism of Clinical Translation and Application of New Biomedical Technologies" (the "Rules"), aiming…

September 12, 2026

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

September 11, 2026

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

September 11, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

Explore Now

Henlius Partners with GeneQuantum on HER2-Targeted ADC GQ1005 Development

Company Deals

GeneQuantum Healthcare

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Empowering Chinese Pharma’s Global Expansion

Henlius Partners with GeneQuantum on HER2-Targeted ADC GQ1005 Development

GeneQuantum Secures $13 Billion Deals with Biohaven and AimedBio for ADC Development

GeneQuantum Healthcare’s GQ1011 (AMB302) Receives FDA Approval for Clinical Study

GeneQuantum Healthcare’s GQ1005 ADC Receives CDE Clearance for Phase III Breast Cancer Trial

GeneQuantum Appoints Dr. Lingyu Zhu as Chief Business Strategy and Development Officer

Nona Biosciences Partners with GeneQuantum Healthcare to Advance Drug Conjugate Discovery

InxMed Partners with GeneQuantum Healthcare to Develop Innovative ADCs

GeneQuantum Healthcare and Aimed Bio Expand Partnership to Develop Five Novel ADC Drugs

About Company